Experts still see some hope for Avastin in adjuvant colon cancer
This article was originally published in Scrip
Executive Summary
Roche's (Genentech) Avastin (bevacizumab) may have failed in its first Phase III trial in adjuvant cancer – one of the most closely watched oncology drug trials of the year – because the duration of treatment with the VEGF-targeted therapy was not long enough, the trial's investigators told a plenary session at this week's ASCO meeting in Orlando. They revealed data showing that Avastin showed a benefit in stopping colon cancer from recurring over the year that it was administered, but this benefit diminished in subsequent years.